The clinical and histopathologic ocular changes identified primarily in HD eyes after IVT dosing with AAV8-eqIL-10 may be driven by the elevated levels of IL-10, leading to a reduction in AAV clearance; by an immune response to the viral capsid or transgenic genome elements; or a combination of both.36 Here, IL10 is linked to Huntington disease.